Senior management

Gunilla Osswald
Gunilla Osswald

Position and role
CEO since 2014. Employed at the company since 2013.

Born
1961

Education
Pharmacist; Ph.D. in biopharmacy and pharmacokinetics at Uppsala University, Sweden.

Other assignments
Board member of PledPharma AB and SpineMedical AB.

Experience and prior assignments
More than 30 years of experience in drug development. Executive positions at Astra/ AstraZeneca, including Vice President responsible for the product portfolio in neu-rodegenerative diseases. Board member of SP Process Development AB, SpineMedical Sverige AB and LPB Sweden Holding AB

Total holdings* and warrants
75,070 Class B shares
Warrants granting acquisition rights to 100,000 Class B shares (2019/2028 program)

Gunilla Andersson
Gunilla Andersson

Position and role
Senior Director HR. Employed since 2019. Contracted since 2014.

Born
1961

Education
B.Sc. Human Resource Development and Labor Relations with a specialization in labor rights from Lund University, Sweden.

Other assignments
Manages her own consulting company focusing on HR.

Experience and prior assignments
30 years of experience as HR consultant and HR manager in educational organizations and pharma companies such as Pharmacia and Novartis.

Total holdings* and warrants
0 shares
Warrants granting acquisition rights to 20,000 Class B shares (2019/2028 program)

Oskar Bosson
Oskar Bosson

Position and role
Vice President Investor Relations & Communications. Employed at the company since 2020.

Born
1976

Education
M.Sc. Molecular Biotechnology and B.A. in Business Administration from Uppsala University

Other assignments

Experience and prior assignments
17 years of experience from the communication field globally. Held senior positions in companies such as Sobi, Ovako and most recently Elekta.

Total holdings* and warrants
3851 Class B shares
Warrants granting acquisition rights to 20,000 Class B shares (2019/2028 program)

Johanna Fälting
Johanna Fälting

Position and role
Vice President Head of Research. Employed at the company since 2012, in her current role since 2020.

Born
1972

Education
Ph.D. in Physiology, Stockholm University; Licentiate degree in physiology, Stockholm University; Master’s degree in biology, Stock-holm University, Sweden.

Other assignments

Experience and prior assignments
19 years of experience in neuroscience/ pharmacology, drug research, translational science and development in the global pharma and biotech industry.

Total holdings* and warrants
38,355 Class B shares
Warrants granting acquisition rights to 20,000 Class B shares (2019/2028 program)

Lars Lannfelt
Lars Lannfelt

Position and role
Senior Vice President University Collaborations. Founder of BioArctic in 2003.

Born
1949

Education
Medical degree (specialist in psychiatry) and doctoral thesis at Karolinska Institutet, Stockholm, Sweden; Associate Professor of Neurogenetics at Karolinska Institutet, specialist in geriatrics.

Other assignments
Board member of Demban AB and LPB Sweden AB.

Experience and prior assignments
More than 35 years of experience in rese-arch into Alzheimer’s disease and other neurodegenerative diseases. Professor of Geriatrics at Uppsala University; Senior Professor at Uppsala University and member of the Royal Swedish Academy of Sciences. Founder of BioArctic in 2003, Chairman of the Board and a number of assignments and roles in the company.

Total holdings* and warrants
8,639,998 Class A shares through Demban AB.
22,628,052 Class B shares through Demban AB.
0 warrants

Christine Lind
Christine Lind

Assignment and role**
Strategy and Business Development Advisor since 2019.

Born
1974

Education
B.Sc. in Finance and Information Systems from New York University, and an MBA in Finance and Management from Columbia Business School.

Other assignments
Chairman of the Board and CEO of Lind Growth Strategy AB. Board member of Immunicum AB and Xspray Pharma AB.

Experience and prior assignments
Previous CEO, Medivir AB and Vice President Business Development, LifeCell Corporation. Worked in investment banking for twelve years, at Merrill Lynch & Co. and Gerard Klauer Mattison & Co., focusing on strategic advisory services and raising of capital for biotech and pharma companies.

Total holdings* and warrants
2,000 Class B shares

Jan Mattsson
Jan Mattsson

Position and role
Vice President Finance, Chief Financial Offi-cer. Employed at the company since 2017.

Born
1960

Education
MBA from Örebro University.

Other assignments Experience and prior assignments
More than 30 years of experience in business and administration, including CFO at Sefina Finance AB, Allenex AB, Argnor Wireless Ventures AB, Logitall AB and Investment AB Kinnevik. Board member of Sefina Svensk Pantbelaning AB and Humidus AB.

Total holdings* and warrants
42,270 Class B shares, privately and through Almsäter Interim Management AB
Warrants granting acquisition rights to 20,000 Class B shares (2019/2028 program

Mikael Moge
Mikael Moge

Position and role
Vice President Chemistry, Manufacturing & Control since 2018 and Director Quality in Operations since 2020. Employed at the company since 2012.

Born
1967

Education
Master of Engineering chemical engineering, KTH Royal Institute of Technology; Ph.D. in organic chemistry, KTH; Stockholm, Sweden.

Other assignments Experience and prior assignments
23 years of experience in drug development and 19 years of experience as R&D director in process development and GMP manufacturing. Former section manager in Process R&D at AstraZeneca.

Total holdings* and warrants
6,825 Class B shares
Warrants granting acquisition rights to 20,000 Class B shares (2019/2028 program)

Christer Möller
Christer Möller

Position and role
Vice President Pre-Clinical Development, Chief Scientific Officer. Employed at the company since 2006.

Born
1959

Education
B.Sc. in Biology, Stockholm University, Sweden; Ph.D. in Medical Science, Karolinska Institutet, Stockholm, Sweden.

Other assignments Experience and prior assignments
21 years of experience in developing protein drugs from idea to clinical trials including leading positions at small biotech/pharma companies such as Zymenex A/S. In addition, comprehensive academic experience in pursuing research projects concerning growth factors and preclinical research in diabetes.

Total holdings* and warrants
43,770 Class B shares
Warrants granting acquisition rights to 20,000 Class B shares (2019/2028 program)

Tomas Odergren
Tomas Odergren

Position and role
Chief Medical Officer (CMO) since January 2020. Previously, Senior Director Clinical Strategy at BioArctic.

Born
1959

Education
MD Uppsala University, PhD Karolinska Institute, Neurologist certified by the Swedish Medical Society, Diploma in Pharmaceutical Medicine EUCOR/ECPM.

Other assignments
Senior Clinical Consultant at GKeller Consulting

Experience and prior assignments
More than 20 years’ experience from the pharmaceutical industry in leading positions in clinical development at AstraZeneca and H Lundbeck. Chief Specialist ICR Neurology H Lundbeck A/S (2015-2017)

Total holdings* and warrants
5,200 Class B-shares
Warrants granting acquisition rights to 20,000 Class B shares (2019/2028 program)

Nora Sjödin
Nora Sjödin

Position and role
Vice President Regulatory Affairs. Employed at the company since 2017.

Born
1957

Education
Licensed nurse. B.Sc.

Other assignments Prior assignments
26 years of experience in leading positions with global regulatory affairs, from early development phases to products in the market, at companies such as AstraZeneca, NDA Regulatory Service and Pharmalink.

Total holdings* and warrants
2,000 Class B shares.
Warrants granting acquisition rights to 20,000 Class B shares (2019/2028 program)

*Includes holdings by self, closely associated persons, controlled companies or otherwise controlled.

**Consultant since November 1, 2019